Atypical Pneumonia: Detecting Mycoplasma, Legionella and Pneumococcus Quickly

Atypical pneumonia is a clinical diagnosis with substantial real-world consequences. The 2023/24 Mycoplasma pneumoniae wave taught primary-care physicians and hospitalists across Europe a hard lesson: the textbook "atypical pneumonia" is no longer rare or geographically limited. In Saxony alone, the only German federal state with a notification requirement for Mycoplasma pneumoniae, more than 12,000 infections were reported by mid-September 2024, an eleven-fold increase over the 2023 baseline of around 1,000 cases. The atypical pathogens are back on the front page of community-acquired pneumonia, and the diagnostic toolbox is finally catching up.

This guide is written for primary-care physicians, internists, hospitalists, and pharmacy staff who want a current, practical reference on the three classic atypical pneumonia pathogens and on the new generation of multi-pathogen point-of-care tests that detect them from a single nasal swab in around ten minutes.

What is atypical pneumonia?

The label "atypical pneumonia" dates back to the 1930s, when clinicians noticed that some patients with pneumonia did not respond to penicillin, did not show classic lobar consolidation on chest X-ray, and presented with a more gradual, systemic illness rather than the abrupt onset of pneumococcal disease. The term has stuck, even though it is somewhat misleading: in 2026, atypical pathogens are responsible for a substantial fraction of community-acquired pneumonia (CAP) in adults.

Three pathogens classically define atypical pneumonia:

• Mycoplasma pneumoniae, a cell-wall-deficient bacterium
• Chlamydophila pneumoniae, an intracellular pathogen
• Legionella pneumophila, an intracellular Gram-negative bacterium

Pneumococcus (Streptococcus pneumoniae) is technically the textbook example of "typical" pneumonia, but it is included in this article because the new multi-pathogen rapid tests detect it alongside the classic atypical trio, allowing point-of-care differentiation that older diagnostic workflows could not deliver.

The three classic pathogens at a glance

Three biological features unite the classic atypical pathogens and explain why they behave differently from pneumococcus:

• Cell-wall biology: Mycoplasma has no cell wall at all. Legionella and Chlamydophila live partly or entirely inside host cells. None of them respond to beta-lactam antibiotics, the workhorse of typical pneumonia therapy.
• Slow, systemic onset: Days of headache, malaise, dry cough, and low-grade fever before the lung findings become prominent. Patients often see two or three doctors before the diagnosis is made.
• Atypical chest X-ray pattern: Bilateral interstitial or patchy infiltrates rather than dense lobar consolidation. The X-ray often looks "worse than the patient sounds."

The German S2k guideline on community-acquired pneumonia in children and adolescents (AWMF register no. 048/013, 2024 revision) and the S3 guideline on adult CAP (AWMF 020-020) both explicitly recommend considering atypical pathogens in the empirical antibiotic decision, which has tangible implications when macrolide use is being weighed.

Mycoplasma pneumoniae: the 2024 surge

Mycoplasma pneumoniae is the smallest free-living bacterium known and the most consequential of the atypical CAP pathogens by case volume. Its lack of a cell wall means beta-lactam antibiotics (penicillins, cephalosporins) are completely ineffective, which is the central diagnostic-therapeutic insight that justifies testing for it.

Epidemiology after the COVID-19 lull

Mycoplasma cycles in waves of approximately three to seven years. After almost vanishing during the COVID-19 lockdowns, it returned with force in 2023 and crested in late 2024. Saxony, the only German federal state with a Mycoplasma pneumoniae notification requirement, reported more than 12,000 infections by mid-September 2024, an eleven-fold increase compared to 2023. Pediatric departments across Europe reported sharp increases in admissions for Mycoplasma pneumonia, often complicated by extrapulmonary features such as Stevens-Johnson syndrome, hemolytic anemia, and encephalitis.

Clinical presentation

• Gradual onset over five to ten days
• Initial features: headache, sore throat, low-grade fever, malaise
• Persistent dry cough that can last six to eight weeks even after the acute illness
• Bilateral patchy infiltrates on chest X-ray
• Cold agglutinins in laboratory testing (a clue that has lost importance with the availability of PCR)
• Extrapulmonary involvement: erythema multiforme, pediatric Stevens-Johnson syndrome with mucosal involvement (MIRM), hemolytic anemia, myocarditis, encephalitis

Macrolide resistance

Macrolide resistance varies dramatically by region. Globally, prevalence is around 28 percent. China leads with rates above 80 percent in some surveillance series. The United States reports under 10 percent. Europe sits at around 5 percent, with Italy as a notable outlier at approximately 20 percent. Germany has remained below 10 percent in recent surveillance, which makes macrolides (azithromycin, clarithromycin) a reasonable empirical first choice in pediatric Mycoplasma pneumonia. From age eight, doxycycline is an alternative, and fluoroquinolones (levofloxacin, moxifloxacin) are options in adults.

Legionella pneumophila: from cooling towers to lungs

Legionella pneumophila is the cause of Legionnaires' disease, a severe pneumonia first identified in a 1976 outbreak among American Legion convention attendees in Philadelphia. Fourteen serogroups are recognized, of which serogroup 1 causes 70 to 90 percent of all clinical infections.

Epidemiology and exposure

Legionella thrives in warm aquatic environments: cooling towers, large building hot-water systems, decorative fountains, hot tubs, and humidifiers. Outbreaks are typically linked to inhalation of contaminated aerosols, not person-to-person transmission. Risk groups include elderly patients, smokers, immunosuppressed individuals, and travelers exposed to hotel water systems.

Clinical presentation

• High fever (often above 39.5 degrees Celsius), often with relative bradycardia
• Severe headache and confusion in some patients
• Productive cough developing after several days
• Pleuritic chest pain
• Diarrhea and abdominal pain in roughly a third of cases (an unusual feature for pneumonia)
• Hyponatremia, elevated transaminases, and creatine kinase elevation in laboratory tests

Pontiac fever

The same organism can cause a self-limiting flu-like illness called Pontiac fever, without pneumonia. Patients recover within a week. It is a reminder that not every Legionella exposure leads to severe disease.

Diagnostic challenges

Classical Legionella diagnostics rely on three pillars: urine antigen testing (sensitivity 60 to 80 percent for serogroup 1, specificity above 95 percent, but blind to all other serogroups), respiratory PCR (high sensitivity, broader serogroup coverage, longer turnaround), and culture on selective BCYE agar (slow but historically the reference standard). The urine antigen test misses up to 30 percent of cases by design.

Streptococcus pneumoniae: the most common cause of CAP

Streptococcus pneumoniae (pneumococcus) remains the single most common bacterial cause of community-acquired pneumonia in adults. Estimates suggest pneumococcus accounts for around half of bacterial CAP cases. While pneumococcus is the textbook example of "typical" pneumonia, modern multi-pathogen rapid tests include it for a clinically obvious reason: ruling it in or out at the point of care reshapes empirical antibiotic decisions.

Clinical presentation

• Abrupt onset, often within hours
• High fever, often with a single rigor
• Productive cough with rust-colored sputum (the classic but inconsistent finding)
• Pleuritic chest pain
• Lobar consolidation on chest X-ray
• Incubation period of one to three days

Resistance and vaccination

Penicillin resistance has increased over the past three decades. Local resistance patterns vary, but the German S3 guideline still recommends aminopenicillins as first-line therapy for uncomplicated CAP unless local resistance data argue otherwise. Pneumococcal vaccination (PCV13, PCV15, PCV20, and PPSV23) substantially reduces invasive disease in older adults and at-risk groups.

Atypical vs. typical pneumonia: how to distinguish them clinically

The clinical distinction between typical and atypical pneumonia is far less clean than older textbooks suggested. Empirical antibiotic decisions today are based on epidemiologic context, severity, and the availability of rapid pathogen detection rather than on symptom patterns alone. Still, certain features tilt the probability:

Feature	Typical (S. pneumoniae)	Atypical (Mycoplasma, Legionella)
Onset	Abrupt, within hours	Gradual, over days
Fever	High, with rigors	Often moderate; high in Legionella
Cough	Productive, rust-colored sputum	Dry, persistent (Mycoplasma); productive later (Legionella)
Chest X-ray	Lobar consolidation	Bilateral patchy or interstitial infiltrates
Extrapulmonary signs	Uncommon	Headache, GI symptoms, hyponatremia, rash
Beta-lactam response	Yes	No (Mycoplasma has no cell wall; Legionella is intracellular)

For a deeper view of overlapping respiratory presentations, see our overview of multiplex panels for bacterial infections.

Diagnosis: from classical workup to nasal-swab point-of-care

For decades, atypical pneumonia diagnosis required either an empirical macrolide or a careful, slow workup combining several methods. The 2026 reality is more nuanced.

The classical reference methods

• RT-PCR from respiratory samples: The reference standard for Mycoplasma, Legionella, and Chlamydophila. Sensitivity above 95 percent, specificity above 99 percent. Sample types: nasopharyngeal swab, throat swab, sputum, BAL. Turnaround: typically 4 to 24 hours.
• Urine antigen test (Legionella, Streptococcus pneumoniae): Bedside-feasible. Detects Legionella pneumophila serogroup 1 only (sensitivity 60 to 80 percent). For pneumococcus, sensitivity is around 70 percent and specificity 90 to 95 percent. Misses non-pneumophila Legionella entirely.
• Culture: Gold standard historically. Mycoplasma is fastidious and slow to grow; Legionella requires selective BCYE agar and several days. Rarely changes acute management.
• Serology: Mainly retrospective. IgM rises late, IgG seroconversion documents past infection. Limited utility in the acute setting.

The point-of-care alternative

The newest generation of multi-pathogen rapid tests has changed what is feasible at the point of care. The parahealth diagnostics 12-in-1 respiratory multitest detects all three classic atypical pneumonia pathogens (Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae) plus nine respiratory viruses (COVID-19, influenza A and B, RSV, adenovirus, human metapneumovirus, rhinovirus, parainfluenza 1/3 and 2) from a single nasal swab in approximately ten minutes.

The cassette uses six dual-detection windows. Validated against RT-PCR in an 851-sample study, all twelve targets exceeded 94 percent positive percent agreement, with no cross-reactivity against more than 40 other respiratory pathogens at 1.0 x 10^6 copies per mL. Interference testing with 26 commonly used medications, nasal sprays, and endogenous substances confirmed no impact on results.

For the primary-care physician evaluating a patient with three days of dry cough, malaise, and a chest X-ray showing bilateral patchy infiltrates, the practical question changes. Instead of "should I empirically add a macrolide and hope I am right?", the question becomes "is Mycoplasma actually present, or is this Legionella, pneumococcus, or a viral process I should treat differently?" That is a meaningfully different conversation, and it can happen during the same visit.

The wider portfolio of respiratory and flu tests covers the full clinical workflow from screening to differential diagnosis.

Limitations of any nasal-swab approach

A nasal-swab antigen test, even at greater than 94 percent PPA, is not a replacement for chest X-ray, blood culture in severe disease, or specialist consultation in immunocompromised patients. It is a tool that accelerates the diagnostic question, not one that closes it. Severe CAP patients should still receive blood and respiratory cultures, urine antigen testing where available, and empirical broad-spectrum coverage per the AWMF S3 guideline.

Antibiotic therapy and resistance situation

Treatment depends on the suspected or confirmed pathogen, severity (CRB-65 in adults), and patient factors:

Mycoplasma pneumoniae

• First-line in children and adolescents: Macrolides (azithromycin, clarithromycin) where local resistance is below 10 percent. The German setting in 2026 still meets this criterion.
• From age 8: Doxycycline is an option.
• Adults: Macrolides or doxycycline; fluoroquinolones (levofloxacin, moxifloxacin) for severe cases or treatment failure.
• Special note: The pediatric S2k guideline AWMF 048/013 explicitly notes that macrolides should not be used as primary therapy for non-severe pCAP because pneumococcus remains the more common pathogen and beta-lactams cover it better. Macrolide use is targeted to confirmed or strongly suspected Mycoplasma cases.

Legionella pneumophila

• First-line: Fluoroquinolones (levofloxacin, moxifloxacin) for moderate to severe cases. Macrolides (azithromycin) are an alternative.
• Duration: 7 to 14 days, longer in immunocompromised patients.
• Source control: Public health investigation of the suspected water source.

Streptococcus pneumoniae

• First-line: Aminopenicillins (amoxicillin), per the German S3 guideline, unless local resistance argues otherwise.
• Penicillin allergy: Macrolides or doxycycline.
• Severe cases: IV ampicillin or ceftriaxone, with adjunctive macrolide if atypical coverage is desired.

Prevention and follow-up

Prevention strategies differ by pathogen:

• Mycoplasma pneumoniae: No vaccine. Prevention relies on respiratory hygiene and case isolation in closed settings.
• Legionella pneumophila: Engineering controls of water systems (temperature, biocides, filtration). The European Technical Guideline EWGLI is the reference framework.
• Streptococcus pneumoniae: Conjugate (PCV13, PCV15, PCV20) and polysaccharide (PPSV23) vaccines for older adults and at-risk groups, per STIKO recommendations.

Follow-up imaging is recommended six to eight weeks after CAP in adults over 50 to exclude underlying malignancy. Mycoplasma cough can persist for two months after the acute illness; this is a normal finding, not treatment failure. For comparable infection-control workflows, see our note on training for handling infectious samples.

FAQ

What is the most common cause of atypical pneumonia?

Mycoplasma pneumoniae, by case volume. Legionella pneumophila is the most common cause of severe atypical pneumonia requiring hospitalization. Chlamydophila pneumoniae rounds out the classic trio.

Can adenovirus also cause atypical pneumonia?

Adenovirus can cause severe pneumonia, particularly in young children, military recruits, and immunocompromised adults. It is not classically grouped with the bacterial atypical pneumonia trio, but a comprehensive respiratory rapid test detects it alongside Mycoplasma, Legionella, and pneumococcus. See our companion article on adenovirus symptoms and testing for the differential.

How long does atypical pneumonia last?

Acute illness typically resolves over 2 to 3 weeks. Mycoplasma cough can persist for 6 to 8 weeks. Full radiographic clearance can take 4 to 8 weeks.

Is atypical pneumonia contagious?

Mycoplasma is contagious through respiratory droplets, especially in close contact settings (households, dormitories, schools). Legionella is environmental and not transmitted person-to-person. Pneumococcus is transmitted in the community but most exposures do not result in pneumonia.

Why do beta-lactams not work for atypical pneumonia?

Mycoplasma has no cell wall, the target of penicillins and cephalosporins. Legionella and Chlamydophila live inside host cells, where beta-lactams achieve poor concentrations. Macrolides, tetracyclines, and fluoroquinolones reach intracellular targets effectively.

Does the 12-in-1 rapid test detect all three atypical pathogens?

Yes. The parahealth diagnostics 12-in-1 respiratory multitest detects Mycoplasma pneumoniae, Legionella pneumophila, and Streptococcus pneumoniae alongside nine respiratory viruses from a single nasal swab in approximately ten minutes. Each pathogen exceeded 94 percent positive percent agreement against RT-PCR in the validation study with 851 samples.

What is the diagnostic gold standard for Mycoplasma pneumoniae?

RT-PCR from a nasopharyngeal or throat swab. Culture is fastidious and slow; serology is mainly retrospective. The 12-in-1 nasal-swab antigen test offers a faster point-of-care alternative when waiting for PCR is not feasible.

Sources and further reading

• AWMF S3 guideline 020-020: Adult community-acquired pneumonia, 2021 with 2024 amendments
• AWMF S2k guideline 048/013: Pediatric community-acquired pneumonia (pCAP), January 2024 revision
• RKI overview on Mycoplasma pneumoniae infection control
• Saxon State Health Authority surveillance data on Mycoplasma pneumoniae 2023/24
• European Working Group for Legionella Infections (EWGLI) technical guidelines
• parahealth diagnostics 12-in-1 multitest IFU and validation data, 851-sample RT-PCR comparison study
• Pharmazeutische Zeitung and Medical Tribune coverage of the 2024 Mycoplasma surge